NCT01330134

Brief Summary

The objective of our study is to determine if technique of lidocaine administration can decrease pain perception. Hypothesis: There will be a significant difference in pain perception between patients who are given lidocaine on the skin surface prior to subcutaneous injection and patients who are given only subcutaneous injection by standard approach.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
481

participants targeted

Target at P75+ for phase_4 pain

Timeline
Completed

Started Feb 2011

Longer than P75 for phase_4 pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 4, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 6, 2011

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
3.2 years until next milestone

Results Posted

Study results publicly available

June 28, 2018

Completed
Last Updated

July 26, 2018

Status Verified

June 1, 2018

Enrollment Period

4.2 years

First QC Date

April 4, 2011

Results QC Date

September 11, 2017

Last Update Submit

June 27, 2018

Conditions

Keywords

procedural

Outcome Measures

Primary Outcomes (1)

  • Pain Assessment: Overall

    Visual analog scale (VAS). This is a standardized analog scale with scores from 0-100. It measures level of pain with 0 meaning no pain and 100 meaning the most extreme level of pain. Higher values refer to a worse outcome.

    post procedure (day 1)

Secondary Outcomes (2)

  • Pain Assessment: Lidocaine Injection

    post procedure (day 1)

  • Pain Assessment: During Procedure

    post procedure (day 1)

Study Arms (2)

lidocaine onto skin prior to lidocaine subcutaneous injection

EXPERIMENTAL

1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.

Drug: lidocaine

lidocaine subcutaneous injection alone

ACTIVE COMPARATOR

1% lidocaine subcutaneous injection alone by standard approach

Drug: lidocaine

Interventions

2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection

lidocaine onto skin prior to lidocaine subcutaneous injection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients refered to the University of Chicago Medical Centers Procedure Service for a planned medical procedure requiring local injection of lidocaine.

You may not qualify if:

  • Patient who lack decisional capacity to consent
  • Patients who lack the ability to answer questions in english using pain scales

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Chicago Medical Center

Chicago, Illinois, 60637, United States

Location

Related Publications (1)

  • Patel BK, Wendlandt BN, Wolfe KS, Patel SB, Doman ER, Pohlman AS, Hall JB, Kress JP. Comparison of Two Lidocaine Administration Techniques on Perceived Pain From Bedside Procedures: A Randomized Clinical Trial. Chest. 2018 Oct;154(4):773-780. doi: 10.1016/j.chest.2018.04.018. Epub 2018 Apr 24.

MeSH Terms

Conditions

Pain

Interventions

Lidocaine

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Results Point of Contact

Title
John P. Kress, MD
Organization
University of Chicago

Study Officials

  • John P Kress, MD.

    Univeristy of Chicago

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2011

First Posted

April 6, 2011

Study Start

February 1, 2011

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

July 26, 2018

Results First Posted

June 28, 2018

Record last verified: 2018-06

Locations